Literature DB >> 10791383

Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe.

.   

Abstract

We compared survival from HIV-1 seroconversion before and during the periods of highly-active antiretroviral therapy (HAART). Survival expectations were substantially better for HIV-1-infected individuals in 1997-98 (HAART period) compared with those in 1986-96 (pre-HAART period). Estimated survival 10 years from seroconversion was also substantially better in the later period.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10791383

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  45 in total

1.  Anonymous reporting of HIV infection: an evaluation of the HIV/AIDS surveillance system in Norway 1983-2000.

Authors:  P Aavitsland; O Nilsen; A Lystad
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

2.  Regional and temporal changes in HIV-related mortality in British Columbia, 1987-2006.

Authors:  Viviane D Lima; Katherine J Lepik; Wendy Zhang; Katherine A Muldoon; Robert S Hogg; Julio S G Montaner
Journal:  Can J Public Health       Date:  2010 Sep-Oct

3.  The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals.

Authors:  R S Janssen; D R Holtgrave; R O Valdiserri; M Shepherd; H D Gayle; K M De Cock
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

4.  Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.

Authors:  Steve A Castillo; Jaime E Hernandez; Cindy H Brothers
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Health and economic impacts of an HIV intervention in out of treatment substance abusers: evidence from a dynamic model.

Authors:  Anke Richter; Brett Loomis
Journal:  Health Care Manag Sci       Date:  2005-02

Review 6.  Monitoring HIV treatment in developing countries.

Authors:  Serena P Koenig; Daniel R Kuritzkes; Martin S Hirsch; Fernet Léandre; Joia S Mukherjee; Paul E Farmer; Carlos del Rio
Journal:  BMJ       Date:  2006-03-11

7.  Early atherosclerosis in HIV-infected patients below the age of 55 years: Slovenian national study.

Authors:  Mateja Pirs; Barbara Eržen; Mišo Sabović; Primož Karner; Ludvik Vidmar; Mario Poljak; Borut Jug; Mojca Mikac; Janez Tomažič
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

Review 8.  The benefits of exercise training for quality of life in HIV/AIDS in the post-HAART era.

Authors:  Joseph T Ciccolo; Esbelle M Jowers; John B Bartholomew
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  HIV serosorting as a harm reduction strategy: evidence from Seattle, Washington.

Authors:  Susan Cassels; Timothy W Menza; Steven M Goodreau; Matthew R Golden
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

10.  Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy.

Authors:  Antonella Mandas; Eugenio Luigi Iorio; Maria Gabriella Congiu; Cinzia Balestrieri; Antonello Mereu; Daniela Cau; Sandra Dessì; Nicoletta Curreli
Journal:  J Biomed Biotechnol       Date:  2009-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.